Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease |
| |
Authors: | Alvise Berti Sara Boukhlal Matthieu Groh Divi Cornec |
| |
Affiliation: | 1. Department of Rheumatology, Santa Chiara Hospital, Trento, Italy;2. Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, Trento, Italyalvise.berti@apss.tn.ithttps://orcid.org/0000-0002-7831-921X;4. INSERM UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, CHU de Brest, Brest, France;5. Department of Internal Medicine, H?pital Foch, National Referral Center for Hypereosinophilic Syndrome (CEREO), Suresnes, France |
| |
Abstract: | ABSTRACTIntroduction: Eosinophilic granulomatosis with polyangiitis (EGPA) usually occurs in patients with late-onset asthma and sustained peripheral blood eosinophilia and classically presents with a clinical multifaceted spectrum of manifestations, which may vary at the different stages of the natural history of the disease.Areas covered: We reviewed EGPA clinical presentation, focusing on clinical manifestations at three different phases of the disease: 1/before the development of overt vasculitis, 2/at vasculitis diagnosis and 3/during the long-term follow-up. An update on current classification criteria and recent therapeutic advances has been provided as well.Expert opinion: Asthma, chronic rhinosinusitis and blood eosinophilia could anticipate the overt vasculitis for years. An atopic background may be present in a subset of patients (25-30%), while ANCA presence varies between 10 and 40%. Systemic vasculitis rapidly occurs and clinical features demonstrating vasculitis processes (neuropathy, purpura, scleritis, alveolar hemorrhage and glomerulonephritis) develop along with systemic symptoms (50%). After vasculitis resolution, asthma remains severe in up to 50% of patients and incidence of isolated-asthma and rhinosinus exacerbations remains constantly high. Different sets of classification criteria have been published so far, and DCVAS diagnostic criteria will be presented soon. Interleukin-5 blockers seem to be promising to control the disease and to spare corticosteroids. |
| |
Keywords: | Severe/uncontrolled asthma eosinophilic asthma eosinophilic granulomatosis with polyangiitis EGPA Churg-Strauss ANCA-associated vasculitis long-term outcomes vasculitis mepolizumab Interleukin-5 |
|
|